STOCK TITAN

Endo International plc - $ENDPQ STOCK NEWS

Welcome to our dedicated page for Endo International plc news (Ticker: $ENDPQ), a resource for investors and traders seeking the latest updates and insights on Endo International plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Endo International plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Endo International plc's position in the market.

Rhea-AI Summary
Endo International plc (ENDPQ) launches PD Pool Hall, an unscripted video series featuring real Peyronie's disease patients discussing their experiences, aiming to raise awareness and education about the condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.64%
Tags
none
-
Rhea-AI Summary
Endo International plc (OTC: ENDPQ) announced new presentations related to Peyronie's disease and XIAFLEX® at the Sexual Medicine Society of North America annual meeting. The presentations aim to advance medical knowledge of PD and support patient outcomes, focusing on pain, ventral curvatures, and non-responders. The company provided grants for the research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.18%
Tags
none
-
Rhea-AI Summary
Endo International plc reported financial results for the third quarter of 2023. Total revenues decreased by 17% compared to the same period last year. Reported loss from continuing operations was $28 million, a significant improvement from the $718 million loss in the third quarter of 2022. Adjusted income from continuing operations increased to $131 million, up from $112 million in the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
Rhea-AI Summary
Endo International's operating company, Par Pharmaceutical, has started shipping colchicine 0.6 mg capsules, the first generic version of Hikma's MITIGARE®, approved by the FDA. Colchicine capsules are used for prophylaxis of gout flares in adults. According to IQVIA™, colchicine capsules sales were approximately $65.4 million for the 12 months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
none
-
Rhea-AI Summary
Endo International to present data on collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis at AOFAS meeting. Results show improvement in nodule hardness and patient satisfaction. Safety profile consistent with previous studies. Treatment patterns for plantar fibromatosis also addressed. CCH not yet approved for use. Phase 3 program to begin later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
100%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
100%
Tags
none
Endo International plc

OTC:ENDPQ

ENDPQ Rankings

ENDPQ Stock Data

70.57k
233.69M
0.65%
0.22%
8.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Dublin

About ENDPQ

endo international plc is a global specialty pharmaceutical company focused on improving the lives of patients while creating value. endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications through our operating companies – endo pharmaceuticals, par pharmaceutical, paladin labs, somar and litha. endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from the dupont merck pharmaceutical company. since that time, the company has expanded to include the following business segments: u.s. branded pharmaceuticals, u.s. generic pharmaceuticals and international pharmaceuticals. endo’s strategy is to maximize value for our key stakeholders by employing an efficient operating model with focused and disciplined execution that allows us to pursue growth opportunities both organically and through selective acquisitions. additionally, we are leveraging